Parasitic Disease Control: Advances, Challenges, Future

Amelia Strauss^*
*Correspondence: Amelia Strauss, Department of Viral Pathobiology, Nordlicht University, Hamburg, Germany, Email:

Introduction

Significant progress has been made in malaria vaccine development, particularly with the RTS,S vaccine, although persistent challenges remain, such as vaccine efficacy, long-lasting immunity, and the need for new targets to combat drug resistance and diverse parasite strains [1].

Advancements in diagnosing Human African Trypanosomiasis have focused on highly sensitive and specific molecular tests and antibody detection methods, which are crucial for early detection and disease control in endemic regions, especially considering the difficulties of traditional microscopy [2].

This assessment comprehensively addresses the global emergence and spread of anthelmintic resistance in human soil-transmitted helminths, highlighting the urgent need for improved monitoring strategies, novel drug development, and integrated control programs to preserve the efficacy of existing treatments and prevent widespread treatment failures [3].

Recent progress in developing vaccines against Toxoplasma gondii focuses on live-attenuated and subunit vaccine candidates, while also discussing challenges like achieving broad protection and long-lasting immunity, underscoring the importance of innovative approaches to control toxoplasmosis in both humans and animals [4].

The success of a decade-long integrated control program in Zanzibar demonstrates how sustained mass drug administration, water, sanitation, and hygiene improvements, along with robust surveillance, have significantly reduced schistosomiasis prevalence, moving towards elimination, yet challenges for complete eradication persist [5].

Recent advancements in the search for new treatments for Chagas disease summarize novel chemical entities and drug repositioning efforts, addressing the challenges in developing safe and effective drugs against Trypanosoma cruzi, and highlighting promising preclinical candidates and strategies for accelerating drug discovery [6].

A current perspective on the complex immune responses elicited by parasitic helminth infections discusses the interplay between host immunity, parasite strategies for immune evasion, and the potential for immunomodulation by helminths, which could inform new therapeutic strategies and vaccine development [7].

The growing threat of emerging parasitic zoonoses, driven by climate change, human population growth, and altered land use, necessitates a One Health approach for surveillance, prevention, and control of these diseases that pose significant public health challenges globally [8].

Rapid advancements in molecular diagnostic tools for gastrointestinal parasitic infections, including PCR-based methods, next-generation sequencing, and isothermal amplification, offer increased sensitivity and specificity for detection, aiding in improved surveillance, treatment, and control strategies [9].

Global environmental changes, including climate change and habitat modification, are reshaping parasite-host interactions, leading to shifts in disease prevalence and the emergence of new parasitic diseases, underscoring the necessity for an ecological understanding to predict and mitigate future health threats [10].

Description

Malaria vaccine development has seen significant strides with the RTS,S vaccine, although challenges remain in vaccine efficacy, long-lasting immunity, and identifying new targets to combat drug resistance and diverse parasite strains [1]. Likewise, recent progress in developing vaccines against Toxoplasma gondii focuses on live-attenuated and subunit candidates, addressing the hurdles of achieving broad protection and sustained immunity. Innovative approaches are crucial for controlling toxoplasmosis in both humans and animals [4].

Advancements in diagnosing Human African Trypanosomiasis emphasize the shift towards highly sensitive and specific molecular tests and antibody detection methods. These are vital for early detection and disease control in endemic regions, particularly given the challenges of traditional microscopy [2]. Similarly, molecular diagnostic tools for gastrointestinal parasitic infections, including PCR-based methods, next-generation sequencing, and isothermal amplification, now offer increased sensitivity and specificity for detection, improving surveillance, treatment, and control strategies [9].

A systematic review assesses the global emergence and spread of anthelmintic resistance in human soil-transmitted helminths. It highlights the urgent need for improved monitoring strategies, novel drug development, and integrated control programs to preserve the efficacy of existing treatments and prevent widespread failures [3]. For Chagas disease, recent advances in drug discovery summarize novel chemical entities and drug repositioning efforts, addressing the complexities of developing safe and effective drugs against Trypanosoma cruzi and highlighting promising preclinical candidates [6].

Zanzibarâ??s decade-long integrated control program successfully reduced schistosomiasis prevalence through sustained mass drug administration, water, sanitation, and hygiene improvements, alongside robust surveillance, moving the region towards elimination. Challenges for complete eradication, however, persist [5]. Understanding the complex immune responses elicited by parasitic helminth infections is also critical. This includes the interplay between host immunity, parasite strategies for immune evasion, and the potential for immunomodulation by helminths, which could inform new therapeutic strategies and vaccine development [7].

The growing threat of emerging parasitic zoonoses is driven by climate change, human population growth, and altered land use. This emphasizes the importance of a One Health approach for surveillance, prevention, and control of these diseases that pose significant public health challenges globally [8]. Moreover, global environmental changes, such as climate change and habitat modification, are reshaping parasite-host interactions. This leads to shifts in disease prevalence and the emergence of new parasitic diseases, underscoring the necessity for an ecological understanding to predict and mitigate future health threats [10].

Conclusion

Recent advancements in parasitic disease control span vaccine development, diagnostics, and treatment strategies. Significant strides have been made in malaria vaccine development, particularly with the RTS,S vaccine, though challenges like efficacy and long-term immunity persist. Similarly, Toxoplasma gondii vaccine research focuses on live-attenuated and subunit candidates, aiming for broad and lasting protection. Diagnosis has seen major improvements, especially for Human African Trypanosomiasis, moving towards highly sensitive molecular and antibody detection methods, crucial for early intervention. Molecular diagnostic tools for gastrointestinal parasitic infections, including PCR and next-generation sequencing, now offer increased sensitivity and specificity for better surveillance and treatment. The battle against drug resistance is prominent, with systematic reviews highlighting the global spread of anthelmintic resistance in human soil-transmitted helminths, necessitating new drugs and integrated control. For Chagas disease, novel chemical entities and drug repositioning efforts are underway to find safe and effective treatments. Integrated control programs have shown success, exemplified by Zanzibar's schistosomiasis elimination efforts through mass drug administration and sanitation improvements. Furthermore, understanding complex immune responses to helminth infections is vital for new therapeutic and vaccine strategies. The broader ecological context reveals emerging parasitic zoonoses driven by climate change and altered land use, emphasizing a 'One Health' approach for prevention. Global environmental changes are reshaping parasite-host interactions, affecting disease prevalence and necessitating an ecological understanding to mitigate future health threats.

 

Acknowledgement

None

Conflict of Interest

None

References

Rego, RM, Farias, JP, Fonseca, R. "Malaria vaccine development: recent progress and future challenges".Front Immunol 14 (2023):1252701.

Indexed at, Google Scholar, Crossref

Buscher, P, Lejon, V, Lehane, MJ. "New frontiers in the diagnosis of human African trypanosomiasis".Expert Rev Mol Diagn 20 (2020):627-638.

Indexed at, Google Scholar, Crossref

Cringoli, G, Rinaldi, L, Maurelli, MP. "The global spread of anthelmintic resistance in human soil-transmitted helminths: a systematic review".PLoS Negl Trop Dis 16 (2022):e0010642.

Indexed at, Google Scholar, Crossref

Innes, EA, Blixt, O, Elsheikha, HM. "Advances in the development of Toxoplasma gondii vaccines".Curr Opin Infect Dis 34 (2021):300-305.

Indexed at, Google Scholar, Crossref

Stothard, RJ, Campbell, SJ, Stensgaard, A. "Schistosomiasis elimination in Zanzibar: a decade of integrated control".Trends Parasitol 36 (2020):84-97.

Indexed at, Google Scholar, Crossref

De RM, Maes, L, Bot, C. "Recent advances in drug discovery for Chagas disease".Drug Discov Today 26 (2021):663-670.

Indexed at, Google Scholar, Crossref

Graham, AL, Maizels, RM, Lawrence, RA. "Immune responses to parasitic helminth infections: an update".Parasite Immunol 45 (2023):e13009.

Indexed at, Google Scholar, Crossref

Lallo, MA, Spickett, A, Moolman, C. "Emerging parasitic zoonoses in a changing world: a review".Vet J 249 (2019):11-19.

Indexed at, Google Scholar, Crossref

Stensvold, CR, Degarege, A, Stothard, RJ. "Advances in molecular diagnostic tools for gastrointestinal parasitic infections".Trends Parasitol 37 (2021):1083-1095.

Indexed at, Google Scholar, Crossref

Brooks, DR, Hoberg, EP, Boeger, WA. "Parasite-host interactions in a changing world: implications for emerging diseases".Trends Parasitol 37 (2021):569-577.

Indexed at, Google Scholar, Crossref